Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 7/20 | 0.56 |
| ▸ | LPAR5 | Q9H1C0 | 7/20 | 0.56 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.50 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16507094 | 0.81 | LPAR1 (0.60) | LPAR1LPAR5RCE1HDAC1HDAC6 | |
| SCHEMBL4467147 | 0.80 | RCE1 (0.52) | LPAR1LPAR5RCE1HDAC1HDAC6 | |
| SCHEMBL1901574 | 0.80 | RCE1 (0.52) | LPAR1LPAR5RCE1HDAC1HDAC6 | |
| SCHEMBL29190281 | 0.80 | HDAC1 (0.60) | HDAC1HDAC6HDAC3HDAC7HDAC10 | |
| SCHEMBL15111089 | 0.78 | RCE1 (0.68) | LPAR1LPAR5RCE1HDAC1HDAC6 | |
| SCHEMBL31035978 | 0.78 | MEN1 (0.54) | HDAC1HDAC6HDAC3HDAC7HDAC10 | |
| SCHEMBL709230 | 0.77 | LPAR1 (0.80) | LPAR1 | |
| SCHEMBL6718505 | 0.76 | MEN1 (0.43) | HDAC1HDAC6HDAC8MEN1KMT2A | |
| SCHEMBL10399486 | 0.76 | RCE1 (0.52) | LPAR1LPAR5RCE1HDAC1HDAC6 | |
| SCHEMBL3054586 | 0.74 | RCE1 (0.60) | LPAR1LPAR5RCE1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900219-B2 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1513534-A2 | COMPOUNDS FOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20030220356-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003084544-A2 | COMPOUNDS DOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220356-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | LPAR1 1141/4885LPAR5 1578/4885RCE1 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.